Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

AKTX Relative to the S&P 500

AKTX Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Akari Therapeutics Plc (NASD:AKTX) seasonal charts above shows that a Buy Date of June 1 and a Sell Date of September 21 has resulted in a geometric average return of 7.24% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 107.24% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

To download AKTX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: AKTX